drugset / Trial / NCT04328480

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

NCT04328480

RandomizedParallel-groupOpen-labelTreatment

Summary

The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement for mechanical ventilation.

Timeline

Start
2020-04-17
Primary completion
2021-04-25
Completion
2021-04-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colchicine Small molecule 0.5 mg Oral

Indications